Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Inside the IgAN Clinic: Shared Decision-Making Into Practice
Jonathan Barratt, MD, PhD
Advancing Patient-Centered, Guideline-Driven Management of Hyperkalemia in Adults With CKD and Associated Comorbidities
June 04, 2026
Glasgow
CKD-aP or Something Else? Decoding the Diagnosis
James Burton, DM, FRCP
Emilio Sanchez, MD, PhD
Kappa-Opioid Settings: Real-World Evidence Insights
Lucio Manenti, MD, PhD
The Patient-Clinician Connection in Managing CKD-aP
Improving Sleep and Mental Health in Patients with CKD-aP
Leonie Kraft, MD
Future Directions in Managing Hyperkalemia in CKD and HF
Javed Butler, MD, MPH, MBA
Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF
Ellie Kelepouris, MD, FACP, FAHA
Patrick Rossignol, MD, PhD
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
Javed Butler, MD
Potassium Binders in Practice: Clinical Trial Evidence
Optimizing IgAN Care: Achieving Lower Proteinuria Targets With Combination Therapy
Sydney Tang, MBBS, MD
Cracking the Case: A Clinical Consult on Potassium Binders in Patients with Chronic Kidney Disease and Heart Failure
Pam R. Taub, MD, FACC, FASPC
Jan T. Kielstein, MD, FASN, FERA
Improving CKD Patient Outcomes with SGLT2 Inhibitors
Gates B. Colbert, MD
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Kidney Academy… but how about a more personalized experience?
Press cancel to remain on Global Kidney Academy. Press the link below or the continue button to keep going.